ライフサイエンスコーパス: rhDNase

コーパス検索結果 (left1)

通し番号をクリックするとPubMedの該当ページを表示します

1 rhDNase therapy is safe and well tolerated in CF patient

2 that recombinant human deoxyribonuclease 1 (rhDNase) reduces airflow obstruction and improves mucoci

3 may justify a clinical trial of aerosolized rhDNase in this population.

4 Our results indicate that aerosolized rhDNase improves FEV1 and FVC independent of CPT.

5 that improvements seen in FEV1 and FVC after rhDNase treatment are independent of chest physical ther

6 improved lung function to the same degree as rhDNase in short-term studies.

7 jet nebuliser, is not as effective as daily rhDNase, although there is variation in individual respo

8 (95% CI -546 to 1510) and that between daily rhDNase and hypertonic saline was pound1409 (440 to 2318

9 However, daily rhDNase showed a significantly greater increase in FEV(1

10 We compared the effectiveness of daily rhDNase, hypertonic saline, and alternate-day rhDNase in

11 ed in random order to 12 weeks of once-daily rhDNase (2.5 mg), alternate-day rhDNase (2.5 mg), and tw

12 in mediator levels from baseline with daily rhDNase and HS was not significant; however, with altern

13 When changes in mediator levels with daily rhDNase were compared with alternate-day rhDNase and HS,

14 (SD 25%), 14% (22%), and 3% (21%) with daily rhDNase, alternate-day rhDNase, and hypertonic saline, r

15 o difference between daily and alternate-day rhDNase (2% [95% CI -4 to 9], p=0.55).

16 f once-daily rhDNase (2.5 mg), alternate-day rhDNase (2.5 mg), and twice-daily 5 mL 7% hypertonic sal

17 ily rhDNase were compared with alternate-day rhDNase and HS, no significant differences were detected

18 hDNase, hypertonic saline, and alternate-day rhDNase in children with cystic fibrosis.

19 12-week cost between daily and alternate-day rhDNase was pound513 (95% CI -546 to 1510) and that betw

20 d 3% (21%) with daily rhDNase, alternate-day rhDNase, and hypertonic saline, respectively.

21 not significant; however, with alternate-day rhDNase, there was an increase in free IL-8.

22 a difference between daily and alternate-day rhDNase.

23 Daily recombinant human deoxyribonuclease (rhDNase) is an established but expensive treatment in cy

24 ety and efficacy of recombinant human DNase (rhDNase) in hospitalized patients with cystic fibrosis (

25 Recombinant human DNase (rhDNase) is an established treatment in cystic fibrosis

26 accumulated data on the glycation process in rhDNase I, formulated with lactose and stored in the dry

27 nsecutively to 12 weeks of once-daily 2.5 mg rhDNase, alternate-day 2.5 mg rhDNase, and twice-daily 7

28 e-daily 2.5 mg rhDNase, alternate-day 2.5 mg rhDNase, and twice-daily 7% HS.

29 Administration of rhDNase was not associated with acute adverse events or

30 We compared the effect of rhDNase and HS on cationic proinflammatory mediators in

31 tistically significant therapeutic effect of rhDNase when added to a regimen of antibiotics and chest

32 s on long-term aerosolized tobramycin and/or rhDNase had worse baseline lung function, but still bene

33 Patients were randomized to receive rhDNase 2.5 mg in 2.5 ml excipient twice a day (n = 43)

34 We were unable to demonstrate that rhDNase reduces airflow obstruction or improves mucocili

35 In summary, we were unable to show that rhDNase or HS promote airway inflammation in CF.

36 ompared with baseline (0.70 +/- 0.05) in the rhDNase group.

37 EV1 and FVC were significantly higher in the rhDNase-treated group than in the placebo group, increas

38 Here, we used rhDNase, which only forms His-His covalent dimers after

WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。